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(57) ABSTRACT 
Compositions and methods for treating neural pathologies are 
provided. In particular, compositions and methods for treat-
ing neural pathologies including axonal degeneration are pro-
vided. The compositions include peptide a-ketomides 
optionally in combination with a second therapeutic agent. 
Another aspect of the invention provides compositions and 
methods for treating hyperproliferative disorders. Exemplary 
compositions for treating hyperproliferative disorders 
include an anti-proliferative agent such as paclitaxel, in com-
bination with a calpain inhibitor such as AK295. 
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KETOAMIDE INHIBITORS IN CHRONIC 
NERVE DISEASE 
2 
SUMMARY OF THE INVENTION 
Aspects of the present invention are directed to composi-
tions containing calpain inhibitors, preferably peptide a-ke-CROSS-REFERENCE TO RELATED 
APPLICATION 
This application claims priority to U.S. Provisional Patent 
Application No. 60/413,506 filed on Sep. 25, 2002, which is 
incorporated herein in its entirety. 
5 toamides, and methods of their use for the treatment of a 
pathology, for example pathologies of the peripheral nervous 
system such as neuropathy, axonal degeneration, or calcium-
induced cell injury. It has been discovered that the systemic 
administration of the peptide a-ketoamides, including for 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
10 example AK295, is an effective treatment for calpain related 
pathologies, in particular, axonal degeneration and peripheral 
neuropathy. 
Aspects of the work described herein were supported by 
Public Health Services grant Nos. 1 ROI GM61964 and 5 POI 15 
NS40405-03 from the National Institutes of Health. There-
fore, the U.S. govermnent has certain rights in the invention. 
BACKGROUND OF THE INVENTION 
Another aspect ofinvention provides pharmaceutical com-
positions for the treatment of hyperproliferative disorders 
including an anti-hyperproliferative agent, for example a 
microtubule stabilizing agent for the treatment of the hyper-
proliferative disorder, in combination with a calpain inhibitor 
such as a peptide a-ketoamide to limit or reduce side effects 
of the anti-hyperproliferative agent such as peripheral neur-
1. Field of the Invention 
20 apathy or cytoskeletal degeneration of sensory neurons. 
This invention relates generally to the use of calpain inhibi-
tors, in particular to methods for the treatment of peripheral 
axonal degeneration. Other aspects of the invention relate to 
the use of peptide a-ketoamide compounds to treat pathologi- 25 
cal conditions including neural pathologies, and combina-
tions of anti-hyperproliferative agents with peptide a-ketoa-
mides for the treatment ofhyperproliferative conditions. 
2. Related Art 
Exemplary anti-hyperproliferative agents include microtu-
bule stabilizing agents such as paclitaxel, also referred to as 
Taxol®. Exemplary calpain inhibitors include peptide a-ke-
toamides, for example peptide a-ketoamides of formula I. 
Additional aspects of the invention are directed to methods 
for the prevention of behavioral, electrophysiological, and 
pathological effects of microtubule stabilizing agents by 
administering a peptide a-ketoamide to a host, for example to 
a host having microtubule-stabilizing-agent-induced behav-
30 ioral, electrophysiological, and pathological effects. The 
structure of an exemplary peptide a-keto amide, AK295, is 
shown below. 
Peripheral neuropathy is a major dose-limiting complica-
tion of commonly used anti-cancer agents, including vincris-
tine, cisplatin, and paclitaxel (Taxol®). Paclitaxel, a micro-
tubule toxin derived from the western yew tree, is particularly 
effective against solid tumors, but causes a predominantly 
sensory neuropathy that may be severe enough to necessitate 35 
cessation of treatment. The neuropathy is characterized by 
degeneration of sensory axons, manifesting clinically as 
numbness, pain, and loss of balance [Lipton, R. B., S. C. 
Apfel, J. P. Dutcher, R. Rosenberg, J. Kaplan, A. Berger, A. I. 
Einzig, P. Wiemik and H. H. Schaumburg (1989). "Taxol 40 
produces a predominantly sensory neuropathy." Neurology 
39 (3): 368-73]. Paclitaxel causes a similar sensory neuropa-
thy in rodents that provides a useful experimental model for 
the treatment of peripheral neuropathies. 
Calpains are ubiquitous cytosolic proteolytic enzymes 45 
involved in both physiological and pathological cellular func-
tions. They are calcium-dependent enzymes belonging to the 
family of cysteine proteases. Limited activation of calpains 
results in modification or activation of protein receptors, 
enzymes, and cytoskeletal proteins. Pathological cellular 50 
insults lead to more generalized calpain activation, resulting 
in cytoskeletal degradation and cell death. 
Calpain activation likely occurs due to sustained elevation 
of intracellular calcium that is a common feature of models of 
neuronal injury [Bartus, R. (1997). "The calpain hypothesis 55 
of neurodegeneration: evidence for a common cytotoxic path-
way." Neuroscientist 3: 314-327]. Thus, there is a need for 
compositions and methods of treating pathologies related to 
calpain activation. 
Because neuronal pathologies, in particular neuropathy, 60 
can have a dramatic impact on quality oflife of patients, there 
AK295 
Pathologies including but not limited to paclitaxel-induced 
axonal degeneration can be treated by administering a peptide 
a-ketoamide to a host either alone, or in combination with 
other therapeutic agents, for example anti-inflammatory 
agents, or anti-hyperproliferative agents. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 is a diagram showing an exemplary injection sched-
ule ofpaclitaxel andAK295. 
FIG. 2 is a line graph showing dose-dependent axonal 
degeneration in DRG cultures. Note that control cultures 
continue to grow (inset) while those exposed to paclitaxel 
demonstrate either slowed growth (5 ng/ml, inset) or progres-
sive axonal death. 
FIGS. 3A-F are photomicrographs of nerve fiber pathol-
ogy. A) control dorsal root; B) ventral root from paclitaxel-
treated mouse; C) dorsal root, paclitaxel, 3 weeks; D) dorsal 
root, paclitaxel and AK295, 3 weeks. E) dorsal root, pacli-
taxel, 6 weeks; F) dorsal root, paclitaxel andAK295, 6 weeks. 
is also a need for compositions and methods for treating these 
disorders, in particular, compositions and methods for treat-
ing pathologies with little or reduced side effects such as 
neuropathy. 65 Note that the ventral root is unaffected and that the AK295-
There is still another need for methods and compositions 
for treating axonal degeneration. 
treated animals show significantly fewer degenerating fibers. 
All photomicrographsx60. 
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FIGS. 4A-C are line graphs showing clinical characteris-
tics of animals treated with paclitaxel, paclitaxel+AK295, 
and controls. Data are plotted as % change as compared to 
pre-treatment values. SNAP=tail sensory nerve action poten-
tial amplitude. (*p<0.05). 
FIGS.SA-Dare graphs showing quantitative data of dorsal 
roots. Panels A and B show the distribution of remaining 
nerve fibers by fiber diameter, and panels C and D show the 
percentage of fibers lost in each size group. Note that the 
number of small fibers decreases with age, reflecting axonal 
growth. 
FIGS. 6A-B are bar graphs showing paclitaxel-mediated 
calpain activation in PC12 cells. Panel A shows time-depen-
dent increase in calpain activity in response to 10 ng/ml 
paclitaxel. Panel B shows dose-dependent calpain activation 
at 24 hours. Cal pain activation is suppressed by addition of 50 
µMAK295. AMC concentration is a direct measure of cal pain 
activity. 
FIGS. 7A-D are confocal images of PC12 cells stained 
with antibody to a-tublin. Panel A shows untreated (control) 
cells with delicate microtubule structures with only occa-
sional mitotic elements. Panel B shows the addition of 50 µM 
AK295 to PC12 cells has little or no effect. Panel C show cells 
24 hours after treatment with paclitaxel (300 ng/ml). Micro-
tubles are bundled (arrow) and there are frequent mitotic 
elements, indicating mitotic arrest. Panel D showsAK295 has 
no effect on tubulin bundling or mitotic arrest on PC12 cells 
treated with paclitaxel. 
FIG. 8 is a bar graph showing results of a Sytox® assay for 
cell death in PC12 cells 24 hours after addition of paclitaxel 
(100 ng/ml). Higher fluorescence correlates with increased 
cell death. A) control; B) AK295 only; C) paclitaxel 100 
ng/ml; D) paclitaxel 100 ng/ml andAK295 50 µM; E) pacli-
taxel 100 ng/ml and JG36 (caspase-3 inhibitor) 50 µM; F) 
JG36 only. 
FIGS. 9A-B are line graphs showing clinical characteris-
tics of rats with STZ diabetes. FIG. 9A shows mean blood 
glucose levels (normal 100 mg/di). Diabetic animals did not 
gain weight, and there was no effect on weight of AK295 
(bottom graph). 
FIGS. lOA-D are bar graphs showing AK295 protects 
against diabetes-induced slowing of nerve conduction veloc-
ity and action potential amplitude. Data and p-values in chart. 
Sci=sciatic, CMAP=compound muscle action potential, 
4 
DETAILED DESCRIPTION OF THE INVENTION 
The present invention may be understood more readily by 
reference to the following detailed description of the inven-
5 tion and the Examples included therein. 
Before the present compounds, compositions and methods 
are disclosed and described, it is to be understood that this 
invention is not limited to specific pharmaceutical carriers, or 
to particular pharmaceutical formulations or administration 
10 regimens, as such may, of course, vary. It is also to be under-
stood that the terminology used herein is for the purpose of 
describing particular embodiments only and is not intended to 
be limiting. 
The peptide a-ketoamides are abbreviated as M1 -AA2 -
15 AA1-CO-NR3 R4. The keto amide portion of the 
molecule, -AA1-CO-NR3R4, is equivalent to -NH-
CHRCO--CO-NR3R4 where the R is the side chain of AA 1 . 
Thus the peptide a-ketoamide AK295 is abbreviated as 
Z-Leu-Abu-CONH-(CH2k4-morpholinyl (AK295). The 
20 Z is a benzyloxycarbonyl group, Leu is a leucine residue, Abu 
is an a-aminobutanoic acid residue, the ketone carbonyl 
group is part of the Abu residue, CONH is the amide of the 
a-ketoamide, and the 4-morpholinyl group is a morpholine 
bound to the methylene chair through thenitrogen atom of the 
25 morpholine ring. 
The term "amino," as used herein, refers to -NH2 or 
derivatives thereof formed by independent replacement of 
one or both hydrogen atoms thereon with a substituent or 
substituents independently selected from alkyl, alkanoyl, 
30 aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, het-
eroarylalkyl, and an amino protecting group. The term "C1_10 
alkoxy," as used herein, refers to a C1 _10 alkyl group, as 
defined herein, attached to the parent molecular group 
35 
through an oxygen atom. 
The term "C1 _10 alkyl" as used herein refers to a branched 
or unbranched hydrocarbon group of carbon atoms, such as 
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, I-butyl, 
and the like or branched or unbranched hydrocarbon groups 
of carbon atoms that either contain double or triple carbon 
40 bonds. 
SNAP=sensory nerve action potential amplitude, 45 
The term "C1 _10 alkylamino," as used herein, refers to a 
C1_10 alkyl group, as defined herein, to which is attached at 
least one amino substituent. The term "C3 _15 cycloalkyl" as 
applied herein is meant to include cyclic hydrocarbon chains. 
Examples of these cyclic hydrocarbon chains include cyclo-
propane, cyclobutane, cyclopentane, cyclohexane, cyclohep-
tane, cyclooctane, cyclononane, cyclodecane, cyclounde-
cane, etc. 
STZ=streptozotocin, IN=insulin treated, AK=AK295 
treated. 
FIGS. llA-F are photomicrographs showing morphology 
and morphometry of sural nerve 8 weeks after treatment. 
There is little morphologic evidence of axonal degeneration, 50 
but morphometry demonstrates that AK295 protects against 
axonal atrophy. There is a trend toward more axons in the 
AK295 treated group. 
FIGS. 12A and 12B are bar graphs showing dose depen-
dent axonal degeneration in response to increasing levels of 55 
glucose. 
FIGS. 13A-C are fluorescence photomicrographs ofDRG 
cultures treated with glucose only (panel C) or glucose with 
AK295 (panel B). Panel A is the normal control showing the 
expected growth of axons over the experimental time period. 60 
Note the relative preservation of axons in the AK295 treated 
culture. Cultures treated for 8 days with 200 mM glucose, 
fixed and stained with MAP-5 axonal marker. 
FIGS. 14A and B are bar graphs showing quantitative 
measure of relative protection of AK295 against high glu- 65 
case-induced axonal degeneration at both 3 and 8 days after 
exposure. 
The term "C2 _12 dialkylamino," as used herein, refers to 
two C1_10 alkyl groups, as defined herein, that are attached to 
an amino substituent. The term "C1 _10 fluoroalkyl," as used 
herein, refers to a C1 _10 alkyl group, as defined herein, to 
which is attached at least one fluorine substituent. 
The term "C1 _10 perfluoroalkyl," as used herein, refers to a 
cl-10 alkyl group in which all of the hydrogen atoms have 
been replaced with fluorine atoms. The term biotinyl, as use 
herein, refers to biotin without the biotin carboxyl hydroxyl 
group. 
By the term "effective amount" of a compound as provided 
herein is meant a nontoxic but sufficient amount of the com-
pound to provide the desired utility, for example to reduce, 
inhibit, prevent, or heal neuronal injury. As will be pointed out 
below, the exact amount required will vary from subject to 
subject, depending on the species, age, and general condition 
of the subject, the severity of the condition or disease that is 
being treated, the particular compound used, its mode of 
administration, and the like. Thus, it is not possible to specify 
US 7,429,560 B2 
5 
an exact "effective amount." However, an appropriate effec-
tive amount may be determined by one of ordinary skill in the 
art using only routine experimentation. 
The term "neurotoxin" means a compound that adversely 
affects cells of the nervous system. Suitable neurotoxins 
include compounds that induce axonal degeneration, for 
example by interfering with the neuronal cytoskeleton, in 
particular with microtubles. Microtubule stabilizers, for 
example Taxol® and Taccalonolides E and A, are preferred 
neurotoxins of the present invention. Taccalonolides E andA 
are described in Tinley TL et al. (2003) Taccalonolides E and 
A. Plant-derived steroids with microtubule-stabilizing activ-
ity. Cancer Res. June 15;63(12):3211-20, which is incorpo-
rated by reference in its entirety. Colchicine, colcemid, 
nocadazol, vinblastine and vincristine are additional exem-
plary neurotoxins that affect microtubles. 
6 
prepare pharmaceutically acceptable acid addition salts of 
such basic compounds of Formula I are those that form non-
toxic acid addition salts, i.e., salts containing pharmacologi-
cally acceptable anions, such as the hydrochloride, hydro bro-
mide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid 
phosphate, isonicotinate, acetate, lactate, salicylate, citrate, 
acid citrate, tartrate, TFA, pantothenate, bitartrate, ascorbate, 
succinate, maleate, gentisinate, fumarate, gluconate, gluca-
ronate, saccharate, formate, benzoate, glutamate, methane-
10 sulfonate, ethanesulfonate, benzenesulfonate, p-toluene-
sulfonate and pamoate [i.e., 1,1 '-methylene-bis-(2-hydroxy-
3-naphthoate )] salts. Those compounds of the Formula I that 
are acidic in nature, are capable of forming base salts with 
various pharmacologically acceptable cations. Examples of 
15 such salts include the alkali metal or alkaline earth metal salts 
and particularly, the sodium and potassium salts. 
The term "pharmaceutically acceptable derivative" refers 
to any homolog, analog, or fragment corresponding to the 
peptide a-ketoamides of the present invention provided 
herein which inhibits protease activity and is relatively non-
toxic to the subject or host. 
The term "pharmaceutically acceptable" means a material 
that is not biologically or otherwise undesirable, i.e., the 
material may be administered to an individual along with the 
The term "Taxol®" is intended to be interchangeable with 
paclitaxel and refers to 5-beta,20-epoxy-1,2-alpha,4,7-beta, 
10-beta, 13-alpha-hexahydroxy-tax-11-en-9-one 4, 10-diac-
etate 2-benzoate 13-ester with (2R,3S)-N-benzoy1-3-pheny 1- 20 
isoserine; 7, l 1-Methano-5H-cyclodeca[3,4]benz[l ,2-b] 
oxete,benzenepropanoic acid derivative; Paclitaxel; TAX; 
Taxal; Taxol; Taxol A; substantially pure optical isomers, 
racemates, prodrugs, and derivatives thereof. The structure of 
paclitaxel is provided below. 25 selected bicyclic compound without causing any undesirable 
biological effects or interacting in a deleterious manner with 
any of the other components of the pharmaceutical composi-
tion in which it is contained. 
ooO ~00 
~I 
~ 
The term "anti-hyperproliferative agent" means a sub-
stance that reduces, inhibits or interferes with aberrant cell 
growth or division. Exemplary anti-hyperproliferative agents 
include but are not limited to anti-cancer agents such as 
paclitaxel, chemotherapy agents, anti-sense polynucleotides, 
enzymatic polynucleotides, polypeptides, dideoxy nucle-
otides, chain terminating nucleotides, antibodies, and small 
molecules. 
The term "hyperproliferative disorder" means a pathology 
resulting from aberrant cell growth or division. 
As used herein, and without limitation, the term "deriva-
30 tive" is used to refer to any compound which has a structure 
derived from the structure of the compounds of the present 
invention and whose structure is sufficiently similar to those 
disclosed herein and based upon that similarity, would be 
expected, by one skilled in the art, to exhibit the same or 
35 similar activities and utilities as the claimed compounds. 
Exemplary Embodiments 
Embodiments of the present invention describe composi-
40 tions and methods for the treatment of a pathology, in par-
ticular a neural pathology such as cytoskeletal degeneration 
of peripheral neurons, peripheral neuropathy, or axonal 
degeneration including sensory neuron axonal degeneration. 
The neural pathology can be related to a disease or condition 
45 such as diabetes, or can be the result of contact with a chem-
cial agent including neurotoxic agents. One of the several 
embodiments of the present invention provides a method for 
treating a neural pathology of the peripheral nervous system, 
for example axonal degeneration, by administering to a 
50 patient a therapeutically effective amount of a compound of 
the formula I: 
M 1-AA2 -AA1-CO-NR3R, 
55 a pharmaceutically acceptable salt, or prodrug thereof, 
wherein 
M 1 is selected from the group consisting of H, NH2 -
The term "calpain related pathology" means an abnormal 
cellular or systemic condition or symptom directly or indi-
rectly caused, in part or in whole, by the activity of a cal pain 60 
CO-, NH2--CS-, NH2-S02-, X-NH--CO-, X2N-
CO-, X-NH-CS-, X2N--CS-, X-NH-S02-, 
X2N-S02-, X--CO-, X--CS-, X-, Y-S02-, 
Y ---0-CO-, Y ---0---CS-, morpholine-CO-, and bioti-protease. 
The term "pharmaceutically acceptable salt(s)", as used 
herein, unless otherwise indicated, includes salts of acidic or 
basic groups that may be present in the compounds of For-
mula I. The compounds of Formula I that are basic in nature 
are capable of forming a wide variety of salts with various 
inorganic and organic acids. The acids that may be used to 
nyl; 
X is selected from the group consisting of H, C1 _10 alkyl, 
c3-15 cyclized alkyl, cl-10 fluoroalkyl, cl-10 alkyl substituted 
65 with J, cl-10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl monosubstituted with K, phenyl 
disubstituted with K, phenyl trisubstituted with K, naphthyl, 
US 7,429,560 B2 
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naphthyl monosubstituted with K, naphthyl disubstituted 
with K, naphthyl trisubstituted with K, C1_10 fluoroalkyl with 
an attached phenyl group, C1_10 alkyl with an attached phenyl 
group, cl-10 alkyl with two attached phenyl groups, cl-10 
alkyl with an attached phenyl group substituted with K, C1_10 5 
alkyl with two attached phenyl groups substituted with K, 
c alkyl withanattachednaphthyl group, cl-10 alkyl with an 
att~~hed naphthyl group substituted with K, C1_10 alkyl with 
an attached phenoxy group, and C1_10 alkyl with an attached 
phenoxy group substituted with Kon the phenoxy group, and 10 
C1_10 alkyl monosubstituted with M2; 
Y is selected from the group consisting ofC1_10 alkyl, C3 _15 
cyclized alkyl, cl-10 fluoroalkyl, cl-10 alkyl substituted with 
J, cl-10 fluoroalkyl substituted with J, 1-admantyl, 9-fluore-
nyl, phenyl, phenyl monosubstituted with K, phenyl disubsti- 15 
tuted with K, phenyl trisubstituted with K, naphthyl, naphthyl 
monosubstituted with K, naphthyl disubstituted with K, 
naphthyl trisubstituted with K, C1_10 fluoroalkyl with an 
attached phenyl group, C1_10 alkyl with an attached phenyl 
group, cl-10 alkyl with two attached phenyl groups, cl-10 20 
alkyl with an attached phenyl group substituted with K, C1_10 
alkyl with two attached phenyl groups substituted with K, 
C1_10 alkyl with an attached naphthyl group, C1_10 alkyl with 
an attached naphthyl group substituted with K, C1_10 alkyl 
with an attached phenoxy group, and C1_10 alkyl with an 25 
attached phenoxy group substituted with K on the phenoxy 
group, M 2, and C1_10 alkyl monosubstituted with M 2; 
M 2 is selected from the group consisting of 2-furyl, 2-tet-
rahydrofuryl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrazinyl, 
2-quinolinyl, 1-tetrahydroquinolinyl, 1-isoquinolinyl, 2-tet- 30 
rahydroisoquinolinyl, and -N(CH2CH2)20; 
J is selected from the group consisting of halogen, C02H, 
OH, CN, N02, NH2, C1_10 alkoxy, C1_10 alkylamino, C2_12 
dialkylamino, C1_10 alkyl-0---CO-, C1_10 alkyl-0-CO-
NH-, C1_10 alkyl-S-, and -N(CH2CH2)20; 35 
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a) H, C1_20 alkyl, C1_20 cyclized alkyl, C1_20 alkyl with a 
phenyl group attached to the cl-20 alkyl, cl-20 cyclized alkyl 
with an attached phenyl group, C1_20 alkyl with an attached 
phenyl group monosubstituted with K, C1_20 alkyl with an 
attached phenyl group disubstituted with K, C1_20 alkyl with 
an attached phenyl group trisubstituted with K, C1_20 cyclized 
alkyl with an attached phenyl group monosubstituted with K, 
C1_10 alkyl with a morpholine [-N(CH2CH2)0] ring 
attached through nitrogen to the alkyl, cl-10 alkyl with a 
piperidine ring attached through nitrogen to the alkyl, cl-10 
alkyl with a pyrrolidine ring attached through nitrogen to the 
alkyl, C1_20 alkyl with an OH group attached to the alkyl, 
--CH2CH20CH2CH20H, C1_10 with an attached 4-pyridyl 
group, cl-10 with an attached 3-pyridyl group, cl-10 with an 
attached 2-pyridyl group, C1_10 with an attached cyclohexyl 
group, -NH--CH2CH2-( 4-hydroxyphenyl), -NH-
CH2CH2-(3-indolyl); 
b)--CH2CH(OH)-R5, and 
c)-(CH2)n-R7 ; 
R5 is selected from the group consisting of phenyl, phenyl 
monosubstituted with J, phenyl disubstituted with J, phenyl 
trisubstituted with J, pentafluorophenyl, 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perfluoroalkyl, C1_10 alkoxy, phenoxy, N02, CN, 
OH, C02H, amino, C1_10 alkylamino, C2_12 dialkylamino, 
C1_10 acyl, and C1_10 alkoxy-CO-, and C1_10 alkyl-S-, and 
-N(CH2CH2)20; 40 1-naphthyl, 1-naphthyl monosubstituted with J, 1-naphthyl 
disubstituted with J, 2-naphthyl, 2-naphthyl monosubstituted 
with J, 2-naphthyl disubstituted with J, 2-pyridyl, 2-quinoli-
nyl, and 1-isoquinolinyl; 
AA 1 andAA 2 side chain blocked or unblocked amino acids 
with the L configuration, D configuration, or no chirality at 
the a-carbon selected from the group consisting of alanine, 
valine, leucine, isoleucine, praline, methionine, methionine 
sulfoxide, phenylalanine, tryptophan, glycine, serine, threo- 45 
nine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, 
glutamic acid, lysine, arginine, histidine, phenylglycine, 
beta-alanine, norleucine, norvaline, alpha-aminobutanoic 
acid, epsilon-aminocaproic acid, citrulline, hydroxyproline, 
omithine, homoarginine, sarcosine, indoline 2-carboxylic 50 
acid, 2-azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylserine, S-me-
thylcysteine, S-ethylcysteine, S-benzylcysteine, NH2--CH 
(CH2CHEt2)-C02H, alpha-aminoheptanoic acid, NH2-
CH(CH2-l-naphthyl)-C02H, NH2--CH(CH2-2-naphthyl)- 55 
C02H, NH2--CH(CH2-cyclohexyl)-C02H, NH2--CH 
(CH2-cyclopentyl)-C02H, NH2--CH(CH2-cyclobutyl)-
C02H, NH2--CH(CH2-cyclopropyl)-C02H, 
trifluoroleucine, 4-fluorophenylalanine, lysine substituted on 
the epsilon nitrogen with a biotinyl group, hexafluoroleucine, 60 
and NH2--CHR 2 --C02H; 
R2 is selected from the group consisting of C1_10 branched 
and unbranched alkyl, C1_10 branched and unbranched 
cyclized alkyl, and C1_10 branched and unbranched fluoro-
alkyl; 
R3 and R4 are selected independently from the group con-
sisting of 
65 
R6 is selected from the group consisting ofC1_4 alkyl, C1_4 
alkyl substituted with phenyl, phenyl, and phenyl substituted 
withJ; 
n=l-6; 
R7 is selected from the group consisting of2-furyl, 2-furyl 
monosubstituted with J, 2-pyridyl, 2-pyridyl monosubsti-
tuted with J, 3-pyridyl, 3-pyridyl monosubstituted with J, 
4-pyridyl, 4-pyridyl monosubstituted with J, 2-quinolinyl, 
2-quinolinyl monosubstituted with J, 1-isoquinolinyl, 1-iso-
quinolinyl monosubstituted with J, 
0---, 
0 
CC) 
I CO-, ('i-N) ~, 
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Aspects of the present invention provide compositions and 
methods for treating neural pathologies by targeting axonal 
degeneration rather than by preventing the death of whole 
neurons or stimulating the growth of whole neurons. By 
inhibiting or preventing axonal degeneration, embodiments 
10 
including all Charcot-Marie-Tooth disorders), demyelinating 
neuropathies with secondary axonal degeneration (Guillain-
Barre group) and idiopathic neuropathies, demyelinating dis-
orders of the central nervous system including multiple scle-
5 rosis, and chronic spinal cord degenerations, genetically 
based and otherwise, comprising the step of administering to 
a patient a therapeutically effective amount of a compound of 
formula I. 
Yet another embodiment of the invention provides a phar-
10 maceutical composition including an anti-hyperproliferative 
agent in combination with a calpain inhibitor, for example a 
peptide a-ketoamide. Exemplary anti-hyperproliferative 
agents include microtubule stabilizing agents such as pacli-
taxel also referred to as Taxol®. Suitable peptide a-ketoam-
15 ides include those of formula I. These compositions provide 
an anti-hyperproliferative effective amount of a anti-cancer 
agent with an effective amount of an agent for reducing the 
side effects associated with the anti-cancer agent. Thus, 
embodiments of the present invention disclose compositions 
20 comprising a combination of anti-cancer agents, for example 
paclitaxel, and peptide a-ketoamide calpain inhibitors. One 
of skill in the art will appreciate that the peptide a-ketoamide 
cal pain inhibitors of the present invention do not directly treat 
hyperproliferative disorders, but instead, are used in combi-
25 nation with anti-cancer agents to minimize side effects of 
anti-cancer agents. 
Still another embodiment of the present invention provides 
a method of treating a hyperproliferative disorder by admin-
istering a pharmaceutical composition comprising a anti-hy-
30 perproliferative agent in combination with a cal pain inhibitor. 
Anti-hyperproliferative agents include microtubule stabiliz-
ers such as paclitaxel, and suitable calpain inhibitors include 
peptide a-ketomides, for exampleAK295. AK295 is a potent 
transition-state reversible inhibitor for both calpain I 
35 (Kr0.14 µM) and calpain II (Kr0.041 µM), and is a less 
effective inhibitor of other cysteine proteases such as cathe-
psin B [Li, Z., A.-C. Ortega-Vilain, G. S. Patil, D.-L. Chu, J. 
E. Foreman, D. D. Eveleth and J.C. Powers (1996). "Novel 
peptidyl a-keto amide inhibitors of calpains and other cys-
40 teine proteases." J. Med. Chem. 39(20): 4089-4098.]. The 
calpain inhibitor can be administered concurrently with the 
anti-proliferative agent or subsequent to the administration of 
the anti-proliferative agent. Additionally, the calpain inhibi-
of the invention can maintain axonal connections between 
neurons and between neurons and their targets thereby pre-
venting or reducing neuropathy. Axonal degeneration can 
occur over extended periods of time and, therefore, other 45 
embodiments of the invention are directed to compositions 
and methods for treating chronic pathologies resulting in 
axonal degeneration rather than rapid onset pathologies such 
tor can inhibit one or both of calpain I and calpain II. 
Representative peptide a-ketoamides of the invention 
include but are not limited to: 
Z-Leu-Nva-CO-NH-CH2 -2-pyridyl, 
Z-Leu-Abu-CO-NH-CH2CH(OH)C6F 5 , 
Z-Leu-Phe-CO-NH-(CH2 ) 2Ph, as stroke. 
The compounds of the present invention can be adminis-
tered in an amount sufficient to inhibit, reduce, or ameliorate 
a pathology of the peripheral nervous system including but 
not limited to peripheral neuropathy, sensory neuron axonal 
degeneration, cytoskeletal degeneration of neurons of the 
peripheral nervous system, toxin-induced peripheral nerve 
cell damage, and calpain-related neuronal pathology. It will 
be appreciated by one of skill in the art that some embodi-
ments of the present invention are directed to compositions 
and methods of treating pathologies of peripheral nervous 
system and not of the central nervous system. 
Other embodiments of the invention describe composi-
tions and methods of treating chronic degeneration of motor 
and or sensory neurons as may be seen in motor neuron 
diseases, peripheral neuropathies due to chronic systemic 
diseases (i.e., diabetes, uremia, liver diseases, infections, 
rheumatologic disorders), genetic mutations (hereditary 
motor/sensory and hereditary sensory neuropathy groups, 
50 Z-Leu-Abu-CO-NH-CH2CH(OH)C6H4 -3-0C6Hi3-
CF 3), 
Z-Leu-Abu-CO-NH-CH2CH(OH)C6Hi 4-0CH2 Ph), 
Z-Leu-Abu-CO-NH-CH2CH(OH)C6Hi 4-0Ph), 
Z-Leu-Phe-CO-NH--CH2 -2-quinolinyl, 
55 Z-Leu-Abu-CO-NH-(CH2 ) 2 C6H4 (3-0CH3 ), 
Z-Leu-Abu-CO-NH-(CH2 ) 2 C6H4 ( 4-0CH3 ), 
Z-Leu-Abu-CO-NH-CH2CH(OH)- l-C10H7 , 
Z-Leu-Phe-CO-NH-( CH2 ) 3 -4-morpholiny 1, 
Z-Leu-Abu-CO-NH-(CH2 ) 2 C6H4 (2-0CH3 ), 
60 Z-Leu-Abu-CO-NH-CH2 -2-quinolinyl, 
Z-Leu-Abu-CO-NH-(CH2 ) 3 -4-morpholinyl (AK295), 
Z-Leu-Abu-CO-NH-( CH2 ) 2 -2-(N-methy lpyrrole ), 
Z-Leu-Phe-CO-NH--CH2 CH(OH)C6H4 -3-0C6H4 (3-
CF3), 
65 Z-Leu-Abu-CO-NH-(CH2 ) 2 C6H5 , 
Z-Leu-Phe-CO-NH-Et, 
Z-Leu-Abu-CO-NH-CH2CH(OC2H5 ) 2 , 
US 7,429,560 B2 
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Z-Leu-Phe-CO-NH--CH2CH(OH)C6H4 ( 4-0Ph), 
Z-Leu-Phe-CO-NH--CH2CH(OH)C6H4 ( 4-0CH2Ph), 
Z-Leu-Abu-CO-NH--CH2C6H5 , 
Z-Leu-Phe-CO-NH-(CH2)2NH-biotinyl, 
Z-Leu-Phe-CO-NH-(CH2)3 -2-tetrahydroisoquinolinyl, 
Z-Leu-Abu-CO-NH--CH2CH(OH)C6H3 (3,4-
(0CH2Ph)2), 
Z-Leu-Abu-CO-NH--CH2CH(OH)C6H4 ( 4-0CH3 ), 
Z-Leu-Nva-CO-NH-(CH2)3 -4-morpholinyl, 
Z-Leu-Abu-CO-NH--CH2-l-isoquinolinyl, 
Z-Leu-Abu-CO-NH-Et, 
Z-Leu-Abu-CO-NH--CH2CH(OH)C6H4 -3-0C6H3 (3,4-
Cl2), 
Z-Leu-Abu-CO-NH-Me, 
Z-Leu-Abu-CO-NH-(CH2)3 - l-imidazolyl, 
Z-Leu-Abu-CO-NH-(CH2)2-3-indolyl, 
Z-Leu-Abu-CO-NH-( CH2)3 -2-tetrahydroisoquinoliny1, 
Z-Leu-Abu-CO-NH--CH2-2-tetrahydrofuryl, 
Z-Leu-Abu-CO-NH--CH2CH(OH)C6H4 ( 4-N(CH3 ) 2), 
Z-Leu-Phe-CO-NH-n-Pr, 
Z-Leu-Abu-CO-NH--CH2CH(OH)-2-C10H7 , 
Z-Leu-Phe-CO-NH-Me, 
Z-Leu-Abu-CO-NH--CH2CH(OH)C6H4 (3-CF 3 ), 
Z-Leu-Abu-CO-NH-(CH2)3 - l-tetrahydroquinolinyl, 
Z-Leu-Abu-CO-NH-(CH2)2C6Hi 4-0H), 
Z-Leu-Abu-CO-NH--CH2CH(OH)C6H2(3,4,5-(0CH3 ) 3 ), 
Z-Leu-Phe-CO-NH-( CH2)3 - l -tetrahydroquinoliny 1, 
Z-Leu-Abu-CO-NH-(CH2)2-2-pyridyl, 
Z-Leu-Abu-CO-NH--CH2-C6Hil,3,3-(CH3 ) 3 -5-0H), 
Z-Leu-Phe-CO-NH--CH2CH(OH)C6H4 (3-CF 3 ), 
Z-Leu-Phe-CO-NH--CH2CH(OH)C6H3 (3,4-
(0CH2Ph)2), 
Z-Leu-Abu-CO-NH-(CH2)5 0H, 
Z-Leu-Abu-CO-NH--CH2CH(OCH3 ) 2, 
Z-Leu-Phe-CO-NH--CH2CH(OH)C6H4 -3-0C6H3 (3,4-
Cl2), 
Z-Leu-Phe-CO-NH--CH2CH(OH)C6H4 (3-0Ph), 
Z-Leu-Phe-CO-NH--CH2CH(OH)C6H4 ( 4-N(CH3 ) 2), 
Z-Leu-Abu-CO-NH--CH2-2-pyridyl, 
Z-Leu-Abu-CO-NH-(CH2)20(CH2)20H, 
Z-Leu-Phe-CO-NH--CH2-2-pyridyl, 
Z-Leu-Abu-CO-NH-(CH2)2NH-biotinyl, 
Z-Leu-Abu-CO-NH--CH2--C6H11 , 
Z-Leu-Phe-CO-NH--CH2CH(OH)C6F 5 , 
Z-Leu-Abu-CO-NH--CH2-2-furyl, 
Z-Leu-Abu-CO-NH-(CH2)3 C6H5 , 
Z-Leu-Abu-CO-NH-(CH2)20H, 
Z-Leu-Abu-CO-NH--CH2CH(OH)C6H4 (3-0Ph), 
Z-Leu-Abu-CO-NH-(CH2)2-4-morpholinyl, 
Z-Leu-Abu-CO-NH--CH2CH(OH)Ph, 
Z-Leu-Abu-CO-NH--CH2-4-pyridyl, 
Z-Leu-Abu-CO-NH-( CH2)3 - l -pyrrolidine-2-one, 
Z-Leu-Phe-CO-NH--CH2CH(OH)Ph, 
Z-Leu-Abu-CO-NH--CH2C6H3 (3,5-(0CH3 ) 2), 
Z-Leu-Nva-CO-NH-CH2CH(OH)Ph, 
Z-Leu-Abu-CO-NH--CH2-8-caffeinyl, 
Z-Leu-Abu-CO-NH-n-Pr, 
Z-Leu-Abu-CO-NH--CH2-3-pyridyl, and 
Z-Leu-Phe-CO-NH--CH2Ph. 
12 
severe enough to be dose limiting. It has been discovered that 
peptide a-ketoamide calpain inhibitors, for example AK295, 
are effective in reducing the clinical and pathological effects 
of neurotoxins such as paclitaxel. The combination of anti-
5 hyperproliferative agents with peptide a-ketoamides pro-
vides a therapeutic agent that is effective in treating hyper-
proliferative disorders such as cancer, while minimizing the 
side-effects of the anti-proliferative agent. It has been discov-
ered that AK295 reduced the severity of axonal degeneration 
10 
caused by paclitaxel in dorsal root ganglion cultures. In mice, 
AK295 similarly reduced the degree of axonal degeneration 
in sensory nerve roots, and improved clinical measures of 
neuropathy, including behavioral and electrophysiological 
15 function. Peptide a-ketoamides given systemically inhibit 
calpains and can improve neurologic function in a clinically 
relevant model of toxic neuropathy. Without being bound by 
theory, it is believed that peptide a-ketoamides work to pre-
vent neuropathy by inhibiting axonal degeneration. Peptide 
20 a-ketoamides can thus be used in other neurological disor-
ders where axonal degeneration is a major feature. 
Chronic calpain inhibition with compositions disclosed 
herein, prodrugs, or pharmaceutically acceptable derivatives 
thereof, are effective in treating chronic axonal degeneration 
25 after exposure to a neurotoxic agent. No toxic side effects of 
AK295 either in culture or in the animal were identified, 
further encouraging the potential usefulness ofthis agent for 
long-term treatments. 
The mechanism of paclitaxel neuropathy is poorly under-
30 stood. Microtubule aggregation in neurons, axons, and 
Schwarm cells has been suggested as a possible mechanism. 
The data provided herein demonstrate that paclitaxel aggre-
gates microtubules and kills cells in culture even in the pres-
ence of AK295. The data also show that paclitaxel can 
35 directly activate cal pains, and that this activation is prevented 
by AK295. Without being bound by any one theory, calpain 
activation may result from a variety of pathological pro-
cesses, and represents a "final common pathway" leading to 
cytoskeletal breakdown and axonal degeneration. Thus, 
40 cal pain inhibition may be protective in many disorders where 
axonal degeneration is a prominent feature. Other diseases 
likely to positively effected by peptide a-ketoamide calpain 
inhibitors are peripheral neuropathies due to genetic muta-
tions, peripheral neuropathies associated with other systemic 
45 diseases including uremia, rheumatologic diseases, liver dis-
eases, and infections, axonal degeneration secondary to pri-
mary demyelinating disorders including inflammatory demy-
elinating neuropathies and multiple sclerosis [Waxman, S. G. 
(1998). "Demyelinating diseases-new pathological 
50 insights, new therapeutic targets [editorial; comment]." N 
Engl J Med 338(5): 323-5]. 
Administration 
This invention also provides a pharmaceutical composition 
55 which comprises a compound according to Formula I and a 
pharmaceutically accepted carrier, dilutent or excipient, 
optionally in combination with an anti-hyperproliferative 
agent. Accordingly, the compounds of Formula I may be used 
Microtubule destabilizing agents, for example paclitaxel 60 
are a highly effective anti-cancer agents that cause peripheral 
neuropathy as its major toxic side effect. Thus, the present 
invention includes compositions and methods for treating 
hyperproliferative disorders such as cancer with an anti-can-
cer agent in combination with a calpain inhibitor for treating 65 
the side effects of the anti-cancer agent. Neuropathy is char-
acterized by degeneration of sensory axons, which may be 
in the manufacture of a medicament. For therapeutic use, the 
peptide a-ketoamides may be administered orally, topically, 
or parenterally. The term parenteral, as used, includes subcu-
taneous injection, intravenous, intramuscular, intrastemal 
injection, or infusion techniques. The dosage depends prima-
rily on the specific formulation and on the object of the 
therapy or prophylaxis. The amount of the individual doses as 
well as the administration is best determined by individually 
assessing each case. 
US 7,429,560 B2 
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The pharmaceutical compos1t10ns containing the active 
ingredient may be in a form suitable for oral use, for example, 
as tablets, troches, lozenges, aqueous or oily suspensions, 
dispersible powders or granules, emulsions, hard or soft cap-
sules, syrups, or elixirs. Dosage levels of the order of0.2 mg 
to 140 mg per kilogram of body weight per day are useful in 
the treatment of the above-indicated conditions (10 mg to 7 
gms per patient per day). The amount of active ingredient that 
may be combined with carrier materials to produce a single 
dosage form will vary depending upon the host treated and the 
10 particular mode of administration. 
For injection, the therapeutic amount of the peptidea-ke-
toamides or their pharmaceutically acceptable salts, deriva-
tives or prodrugs will normally be in the dosage range from 
0.2 to 140 mg/kg of body weight. Administration is made by 
intravenous, intramuscular, or subcutaneous injection. 15 
Accordingly, pharmaceutical compositions for parenteral 
administration will contain from about 10 mg to 7 gms of the 
compounds per dose. In addition to the active ingredient, 
these pharmaceutical compositions will usually contain a 
buffer, e.g. a phosphate buffer which keeps the pH in the range 20 
from 3.5 to 7 and sodium chloride, mannitol, or sorbitol for 
adjusting the isotonic pressure. 
A composition for topical application can be formulated as 
an aqueous solution, lotion, jelly or an oily solution or sus-
pension. A composition in the form of an aqueous solution is 25 
obtained by dissolving the compounds of this invention in 
aqueous buffer solution of pH 4 to 6.5 and, if desired, adding 
a polymeric binder. An oily formulation for topical applica-
tion is obtained by suspending the compounds ofthis inven-
tion in an oil, optionally with the addition of a swelling agent 
such as aluminium stearate and/or a surfactant. 30 
Materials and Methods 
Paclitaxel-inducedAxonal Degeneration in Rat DRG Cul-
ture 
14 
S. Patil, D.-L. Chu, J. E. Foreman, D. D. Eveleth and J. C. 
Powers (1996). "Novel peptidyl a-keto amide inhibitors of 
cal pains and other cysteine proteases." J. Med. Chem. 39(20): 
4089-4098]. TheAK295 treatment groups received subcuta-
neous injections of AK295 ( 48 mg/kg) with each paclitaxel 
injection. After the last paclitaxel injection, a 100 µl Alzet 
pump (Alza Corporation, Mountain View, Calif.) filled with 
AK295 (84 mg/ml in DMSO/PEG 300, 1:1), was surgically 
implanted under the back skin. These pumps are designed to 
deliver drug at a rate of 6 µl per day for 14 days, translating 
into 0.504 mg/day, or 24 mg/kg/day for an average 18 g 
mouse. The 6-week treatment group received AK295 injec-
tions with the second paclitaxel treatment and had a new 
pump implanted for the remainder of the study. Control ani-
mals received initial injections with diluent only, and received 
pumps containing diluent only. 
Animals were killed by perfusion with 4% paraformalde-
hyde (in O.lM PBS buffer, pH 7.4) at thetime points depicted 
in FIG. 1. The nerve roots (L4 dorsal and ventral) were har-
vested and post fixed overnight in 5% buffered glutaralde-
hyde at 4° C. Nerve roots were rinsed with PBS buffer, pro-
cessed by standard methods, and embedded in plastic for light 
microscopy. Sections of 780 nm were stained with toluidine 
blue for microscopy study and image analysis. 
Image Analysis 
Images of dorsal and ventral roots (125x) were captured 
using a Kodak DCS-5 digital camera attached to an Olympus 
BH-2 microscope. Multiple overlapping images were cap-
tured, including all axons within the cross section. These 
images were combined into a montage so that the individual 
nerve fibers did not appear more than once. Images were 
analyzed using ImagePro software (Media Cybernetics, Sil-
ver Spring, Md.) running on a Gateway personal computer. 
All myelinated axons were counted. Axonal density was cal-
culated by dividing the number of axons by the area of nerve 
35 cross-section. The diameter and area of each remaining axon 
was measured by tracing the inner boarder of myelin. All data 
were subjected to ANOVA. 
Dorsal Root Ganglion (DRG) from El 5 rats were dissected 
and stripped from connective tissue into L15 medium 
(GIBCO), washed twice with PBS, and plated in collagen 
coated dishes containing DMEM with 1 % N2 supplement 
and 7S NGF (100 ng/ml). Cultures were kept at 37° C., 5% 
C02 . After 5 days of growth, media was changed to that 40 
containing test agents (paclitaxel, AK 295), and DRG 
remained in culture for an additional 10 days. Paclitaxel was 
dissolved in Cremophor EL/ethanol (50:50); final concentra-
tion of Cremophor EL and ethanol in cultures are less than 
0.0001 %. AK295 was dissolved in DMSO with a final con-
centration of DMSO in culture of 0.05%. This amount of 
DMSO demonstrated no effects on DRG growth. 
Serial Images ofDRG were captured on day 0, 4, 8 and 10. 
The area of the DRG halo at each time point was normalized 
Behavioral Testing 
To evaluate changes in neuromuscular function, animals 
were subjected to testing on a Rotarod apparatus (Columbus 
Instruments, Columbus, Ohio) before paclitaxel treatments 
and prior to sacrifice. The initial speed was set at 1.6 rpm with 
acceleration rate of 4 rpm/min. Animals were acclimated to 
the Rotarod for three consecutive days before the test date. 
45 The test was repeated 3 times during each testing session with 
at least 2 minutes of rest between each test. The best perfor-
mance of each session was recorded. Percent changes were 
calculated and analyzed using ANOVA with post-test com-
to the area measured on day 0 (day test agents added), 
enabling each DRG to serve as its own control. Data were 50 
subjected to ANOVA, with post-test correction for multiple 
comparisons. 
parisons. 
Electrophysiology 
Nerve conduction studies were performed using standard 
equipment (Nicolet, Madison, Wis.) on anesthetized animals 
on the same schedule as Rotarod testing. For hind limb Paclitaxel Neuropathy andAK295 Treatment in Mice 
Eight-week-old female C57BL/6J mice were separated 
into 4 treatment groups as outlined in FIG. 1. All groups were 
treated with paclitaxel and two groups were treated with a 
combination of paclitaxel and AK295. Three-week and 
6-week protocols were investigated. paclitaxel was dissolved 
50150 in Cremophor EL/ethanol and diluted 1: 1 with saline; 
final concentration was 7 .5 mg/ml. Each paclitaxel treatment 
consisted of3 injections of 60 mg/kg into the jugular vein on 
an every other day schedule. The 3-week groups received one 
paclitaxel treatment and the 6-week groups received two 
paclitaxel treatments. Control groups were treated with the 
Cremaphor diluent only. 
AK295 (Z-Leu-Abu-(CH2k4-morpholinyl) was synthe-
sized as previously described [Li, Z., A.-C. Ortega-Vilain, G. 
55 recording, the recording electrodes were inserted into the 
interosseous muscles of the left foot; stimuli were adminis-
tered at the ankle and at the hip (sciatic notch) close to the 
tibial and sciatic nerve, respectively. A ground electrode was 
inserted subcutaneously into the tail. Compound muscle 
action potentials were recorded (maximum) and nerve con-
60 duction velocities were calculated. For tail nerve recording, 
the recording electrodes were placed at the base of the tail, 
keeping the anode and the cathode approximately 5 mm apart. 
Stimuli were administered 4-5 cm distal. A ground electrode 
was placed in between the stimulus and recording electrodes. 
65 The sensory nerve action potential was averaged over 50-80 
stimuli, and the amplitude was recorded. Sensory conduction 
velocity was also calculated. 
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Calpain Activation Assay: 
PC12 cells were grown for 24 hours in DMEM with 10% 
horse and 5% fetal calf serums. Cal pain activity in response to 
paclitaxel was assessed in relation to dose (1, 10, 50, or 100 
ng/ml for 24 hours) and of time of exposure (10 ng/ml of 5 
paclitaxel for up to 48 hours). After exposure, cells were 
suspended in KRH buffer (25 mM Na-HEPES, 115 mM 
NaCl, 5 mM KC!, 1 mM KH2P04, 1.2 mM MgS04, 2 mM 
CaCl2, 0.2%1 BSA, pH 7.4) and 2 ml of cell suspension was 
transferred to test tube. The reaction was started by adding 10 
100 µL of the cell-permeable calpain substrate (Suc-Leu-
Leu-Val-Tyr-AMC, 0.84 mg/ml). The suspension was mixed 
immediately and incubated at 37° C. for 15 minutes. The 
reaction was stopped by adding 100 µL 0.4 N HCI. After 
sonication and centrifugation, free AMC in the supernatant 
was measured using a microplate reader 0'-ex355/A.em460). A 15 
standard curve was constructed using AMC standard. Cal pain 
activity was expressed as AMC concentration (pM) per 106 
cells. 
Experimental Neurology 59(7): 599-606.]. Addition of 
AK295 (50 µM) to the culture media provided about 50% 
protection against axonal degeneration induced by 25 ng/ml 
paclitaxel for up to 8 days, as measured by the area of the 
DRG halo (data not shown). 
Example 2 
AK295 Protects Against Paclitaxel Neuropathy in 
Mice 
Paclitaxel caused dose-dependent axonal degeneration in 
mice. Two doses (3x30 mg/kg and 3x60 mg/kg) were tested. 
The low dose caused axonal degeneration in relatively few 
fibers, with inconsistent numbers of degenerating fibers (data 
not shown). The higher dose caused degeneration of a signifi-
cant number of sensory fibers (FIGS. 3A-F), which was 
reproducible and suitable for our purpose of quantitative 
Imaging of Microtubule Aggregates: 
PC12 cells were cultured on collagen-coated coverslips for 
20 
analysis. paclitaxel did not cause axonal degeneration in 
motor fibers. 
48 hours and then treated for 24 hours with paclitaxel or AK 
295. After treatment cells were fixed with 4% paraformalde-
hyde for 30 minutes and post-fixed with pre-cooled methanol 
for 5 minutes at -20° C. The cells was then rinsed with PBS 25 
Nineteen mice were used for the 3-week protocol: control 
(4), paclitaxel (7) and paclitaxel plus AK295 (8). Ten mice 
were used for the 6-week protocol: control ( 4 ), paclitaxel (3) 
and paclitaxel plus AK 295 (3). The animals treated with 
paclitaxel or paclitaxel plus AK295 showed weight loss of 1 and stained with antibody to a-tubulin using standard immu-
nofluorescence staining methods. The cells were imaged on a 
Zeiss LSM 510 confocal microscope for identification of 
microtubule aggregates and mitotic figures. 
Cytotoxicity Assay: 
PC12 cells were cultured in 96 well plates containing 
DMEM supplemented with 10% horse serum and 5% fetal 
calf serum, 200 µI/well. At 80% confluence 100 µI medium 
was replaced with 50 µI Sytox® (Molecular Probes, 
www.molecularprobes.com, final concentration 4 µM) and 
50 µI of the experimental compounds (paclitaxel 10, 100, 200 
or 100 ng/ml, AK295, 50 µM). The caspase inhibitor JG36 
(Cbz-Asp-Glu-Val-AAsp-EP-COOEt) was synthesized in 
our laboratory. JG36 is highly active against caspase-3 and 
little activity against other cysteine proteases [Asgian, J. L., 
K. E. James, Z. Z. Li, W. Carter, A. J. Barrett, J. Mikolajczyk, 
to 3 grams in the first week, but regained a normal growth rate 
and were in good health for the remainderof the study (FI GS. 
4A-C). Rotarod and electrophysiological measures supported 
30 the presence of peripheral neuropathy (FIG. 4), and patho-logical analysis of dorsal roots demonstrated significant loss 
of myelinated fibers at the 3-week time point (Table 1 ). There 
was little evidence of further progression of neuropathy in 
animals receiving a second paclitaxel treatment during the 
fourth week and evaluated at the 6-week time point. Pilot 
35 experiments, however, demonstrated almost full recovery of 
myelinated fiber numbers at 6 weeks in animals not receiving 
a second paclitaxel treatment (data not shown), suggesting 
that the second paclitaxel treatment had the effect of main-
taining the neuropathy in animals that otherwise would have 
40 recovered. Analysis of fibers grouped by diameter demon-
strated that axonal loss was most prominent in larger fibers 
(FIGS. SA-D), as has been demonstrated in paclitaxel neur-
opathy in humans and rats. 
G. S. Salvesen and J. C. Powers (2002). "Aza-peptide 
epoxides: a new class of inhibitors selective for clan CD 
cysteine proteases." J Med Chem 45(23): 4958-60.]. Fluores-
cence C"-ex485/"-em538) was measured immediately and at 45 
scheduled time points for up to 24 hours. After the last read-
ing, 50 µI of 4% paraformaldehyde was added to each well 
and the plate was kept at 4 ° C. for one hour followed by a final 
reading for the maximal amount of fluorescence release. The 
experimental protocol was repeated three times. 
AK295 treatment was protective against paclitaxel induced 
neuropathy by all measures. Behavioral and electrophysi-
ological testing showed protection in the AK295 group at 3 
weeks that persisted to 6-week time point (FIGS. 4A-D). 
Comparing pre- and post-treatment measures, animals 
treated with diluent only improved by about 20% on the 
50 Rotarod (not shown), whereas performance in Paclitaxel-
treated mice was reduced to about 60% of baseline. Pacli-
taxel + AK29 5-treated mice remained at baseline levels. Simi-
lar results were obtained from sensory nerve conduction 
studies. Tail SNAP in Paclitaxel-treated mice was reduced to 
about 50% of baseline, whereas paclitaxel+AK295-treated 
EXAMPLES 
Example 1 
AK295 Protects Against Paclitaxel-induced Axon 
Degeneration in DRG Culture 
Exposure to paclitaxel caused dose-dependent axonal 
degeneration in cultured dorsal root ganglia. Doses of 25 
ng/ml or greater caused rapid axonal degeneration; a dose of 
5 ng/ml did not cause obvious degeneration but did slow 
axonal growth (FIG. 2). Degeneration occurred in a distal to 
proximal pattern ("dying back") similar to that seen in DRG 
cultures exposed to vincristine [Wang, M. S., Y. Wu, D. G. 
Culver and J. D. Glass (2000). "Pathogenesis of axonal 
degeneration: parallels between Wallerian degeneration and 
vincristine neuropathy." Journal of Neuropathology and 
55 mice showed no reduction in sensory amplitudes. There were 
no significant effects of paclitaxel on motor conduction stud-
ies in either sciatic or tail nerves (not shown). 
Pathologically, the degree of axonal degeneration was less 
in AK295-treated mice as compared to mice treated with 
60 paclitaxel only (FIGS. 3A-F and Table 1). Quantitative analy-
sis demonstrated an increase in fiber number and density at 
both3 and 6 weeks in theAK295 group (Table 1). Meanfiber 
diameter was also increased toward normal in these groups 
(Table 1 ). Subgroup analysis of the effects of paclitaxel and 
65 AK295 by fiber size demonstrated the large-fiber predomi-
nance of paclitaxel toxicity and the relative protection by 
AK295 in these larger fibers (FIGS. SA-D). 
US 7,429,560 B2 
17 
TABLE 1 
Morphometry of dorsal root axons, mean± SEM 
Mean Axon 
Groups Total Axons Diameter Axons/mm2 
Control, 3 w 2168 ± 173 2.37 ±0.11 33760 ± 1731 
Paclitaxel, 3 w 1099 ± 76 1.89 ± 0.08 26806 ± 2496 
paclitaxel + AK295, 1378 ± 96* 2.08 ± 0.13 29134 ± 1569 
3w 10 
Control, 6 w 2107 ± 141 3.09 ±0.13 28207 ± 2175 
Paclitaxel, 6 w 1350 ± 98 2.56 ±0.12 17733 ± 1654 
paclitaxel + AK295, 1620 ± 73* 3.10 ± 0.04* 19560 ± 1061 
6w 
*p < 0.05, paclitaxel + AK295 vs. paclitaxel only. 3 w ~ 3 weeks, 6 w ~ 6 15 
weeks. 
Example 3 
Paclitaxel-induced CalpainActivation in PC12 Cells 20 
PC 12 cells were used to demonstrate that exposure to pacli-
taxel can induce calpain activation and that AK295 inhibits 
calpain activity. In PC12 cells there was both time and dose-
dependent increase in calpain activity as measured by cleav- 25 
age of a synthetic calpain substrate (FIGS. 6A-B). AK295 
inhibited calpain-mediated cleavage of the substrate. It is of 
interest to note thatAK29 5 reduced the baseline cal pain activ-
ity measured in non-treated cells as well, without causing any 
apparent toxicity. 
Example 4 
30 
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Cultured DRG from El 5 rats were also exposed to various 
levels of glucose in order to test the protection of AK295 
against axonal degeneration due to glucose toxicity (FIGS. 
12A-B and FIGS. 13A-C). 
In these whole animal and cell culture models of diabetes-
related neuropathy we show that there is protection by AK295 
against measures of nerve function (conduction velocity and 
nerve amplitude), and protection against axonal degeneration 
(FIGS. 14A-B). 
TABLE2 
treatment SciCMAP SciNCV Tail SNAP TailNCV 
control 19.88 ± 5.20 52.33 ± 2.19 57.64 ± 3.39* 51.67 ± 1.45 
STZ 20.43 ± 7.92 33.00 ± 4.04 37.61±11.05 32.00 ± 2.08 
STZ+ 10.99 ± 0.40 33.67 ± 1.76 41.52 ± 0.46 34.33 ± 1.86 
insulin 
STX+ 16.32 ± 2.34 47.00 ± 4.04 71.33 ± 14.39 40.00 ± 1.00 
insulin+AK 
P-value 0.04 0.04 0.005 0.028 
(Ttest,AK 
vs.no AK) 
TABLE3 
Morohometric analysis of sural nerve after 8 weeks treatment 
group diameter (µrn) area (µrn2) #of axons 
control 3.81 ± 0.09 11.74 ± 0.65 668 ± 65 
STZ +insulin 3.57 ± 0.042* 10.37 ± 0.19* 680 ± 19 
STZ + Insulin +AK 4.07 ± 0.097* 13.72 ± 0.65* 738 ± 70 
p value *0.0044 *0.004 
The following table lists inhibition data for calpain I and Paclitaxel-induced Tubulin Aggregation and Cell 
Death 
35 calpain II for the a-ketoamides M
1
-Leu1-AA-CONH-R2. 
Inhibition of calpain correlates with potency in the above 
animal and cell based models. The following values are 
inhibitory potency (KI) values in micromolar. Inhibitors with 
lower numbers are more potent. 
The antineoplastic effects of paclitaxel are based on its 
capacity to bind and stabilize microtubules, leading to mitotic 
arrest, activation of caspases and cell death. We were con-
cerned that inhibition of calpains withAK295 might interfere 
with Paclitaxel-mediated cell death. To address this issue we 40 
used PC12 cells to assess the effect of AK295 on the forma-
tion of tubulin bundles and caspase-mediated cell death in 
response to paclitaxel exposure. PC12 cells showed aggrega-
tion of a-tubulin after exposure to paclitaxel with or without 
addition of AK295 (FIGS. 7 A-D). The frequency of mitotic 45 
arrest was also unchanged in cells treated with AK295. The 
Sytox® cytotoxicity assay showed cell death after exposure 
to paclitaxel that was unaffected by the presence of AK295 
(FIG. 8). Addition of a caspase-3 inhibitor reduced cell death 
to control levels. 
Example 5 
Calpain Inhibition withAK295 in a Model of 
Diabetic Neuropathy 
AK295 was tested for its ability to modify the clinical and 
pathological features of diabetes mellitus-related peripheral 
neuropathy. Wistar rats (male, 9 weeks old) were treated with 
50 
55 
a single dose (75 mg/kg iv) of the pancreatic toxin streptozo-
tocin (STZ), causing them to become diabetic (FIGS. 9A-B). 60 
This was an 8-week study with 4 groups: 1) control (no STZ), 
2) STZonly, 3) STZ+Insulin, 4) STZ+Insulin+AK295 (FIGS. 
lOA-D, FIGS. llA-F, and Tables 2 and 3). Insulin was given 
2x/week based on the measurement of serum glucose at a 
dose of 8µ/100 mg/di. AK295 as provided as a continuous 65 
subcutaneous infusion via pump at a dose of 20 mg/kg/day 
based on a 300 gram rat. 
M1 AA1 
z Nva 
z Abu 
z Phe 
z Abu 
z Abu 
z Abu 
z Phe 
z Abu 
z Abu 
z Abu 
z Phe 
z Abu 
z Abu 
z Abu 
z Abu 
z Phe 
z Abu 
z Phe 
z Abu 
z Phe 
z Phe 
z Abu 
z Phe 
z Phe 
z Abu 
z Abu 
z Nva 
TABLE4 
Cal12ain Inhibition Data 
R2 
CHr2-pyridyl 
CH2CH(OH)C6F5 
(CH2JoPh 
CH2CH(OH)C6H4-3-0C6H4(3-CF3) 
CH2CH(OH)C6H4(4-0CH2Ph) 
CH2CH(OH)C6H4(4-0Ph) 
CHr2-quinolinyl 
(CH2JoC6H4(3-0CH3) 
(CH2)oC6H4(4-0CH3) 
CH2CH(OH)-1-C 10H7 
(CH2)3-4-morpholinyl 
(CH2JoC6H4(2-0CH3) 
CHr2-quinolinyl 
(CH2h-4-morpholinyl (AK295) 
(CH2)o-2-(N-methylpyrrole) 
CH2CH(OH)C6H4-3-0C6H4(3-CF3°) 
(CH2JoC6Hs 
Et 
CH2CH(OC2Hsh 
CH2CH(OH)C6H4(4-0Ph) 
CH2CH(OH)C6H4(4-0CH2Ph) 
CH2C6H5 
(CH2)oNH-biotinyl 
(CH2)3-2-tetrahydroisoquinolinyl 
CH2CH(OH)C6H3(3,4-(0CH2Ph)2) 
CH2CH(OH)C6H4(4-0CH3) 
(CH2)3-4-morpholinyl 
Cal I Cal II 
0.019 0.12 
0.05 0.2 
0.052 0.024 
0.07 0.28 
0.08 0.12 
0.1 0.29 
0.11 0.023 
0.11 0.086 
0.12 0.046 
0.12 0.17 
0.12 0.33 
0.13 0.16 
0.13 0.6 
0.14 0.041 
0.16 0.076 
0.18 0.45 
0.2 0.022 
0.2 0.039 
0.2 0.16 
0.2 0.17 
0.2 0.24 
0.2 0.35 
0.22 0.16 
0.22 0.2 
0.23 0.1 
0.24 nldpf 
0.25 0.1 
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TABLE 4-continued 
Cal2ain Inhibition Data 
M1 AA1 R2 Cal I Cal II 
z Abu CHr 1-isoquinolinyl 0.25 0.15 
z Abu Et 0.25 0.21 
z Abu CH2CH(OH)C6H4-3-0C6H3(3,4-Cl2) 0.27 0.12 
z Abu Me 0.28 0.083 
z Abu (CH2h-1-imidazolyl 0.29 0.068 10 
z Abu (CH2)o-3-indolyl 0.3 0.05 
z Abu (CH2)3-2-tetrahydroisoquinolinyl 0.31 0.19 
z Abu CHr2-tetrahydrofuryl 0.33 0.066 
z Abu CH2CH(OH)C6H4(4-N(CH3)o) 0.33 0.41 
z Phe n-Pr 0.35 0.05 
z Abu CH2CH(OH)-2-C 10H7 0.35 0.11 15 
z Phe Me 0.35 0.15 
z Abu CH2CH(OH)C6H4(3-CF3) 0.35 0.18 
z Abu (CH2h-1-tetrahydroquinolinyl 0.37 0.2 
z Abu (CH2JoC6H4(4-0H) 0.38 0.06 
z Abu CH2CH(OH)C6H2(3,4,5-(0CH3)3) 0.38 0.22 
z Phe (CH2h-1-tetrahydroquinolinyl 0.38 0.26 
z Abu (CH2)o-2-pyridyl 0.41 0.47 20 
z Abu CHr...{:6H7(1,3,3-(CH3)3-5-0H) 0.42 0.069 
z Phe CH2CH(OH)C6H4(3-CF3) 0.46 0.29 
z Phe CH2CH(OH)C6H3(3,4-(0CH2Ph)o) 0.48 0.67 
z Abu (CH2),0H 0.5 0.051 
z Abu CH2CH(OCH3)2 0.5 0.1 
z Phe CH2CH(OH)C6H4-3-0C6H3(3,4-Cl2) 0.59 0.12 25 
z Phe CH2CH(OH)C6H4(3-0Ph) 0.6 0.34 
z Phe CH2CH(OH)C6H4(4-N(CH3)o) 0.62 0.31 
z Abu CHr2-pyridyl 0.64 0.017 
z Abu (CH2JoO(CH2JoOH 0.65 0.16 
z Phe CHr2-pyridyl 0.65 0.27 
z Abu (CH2)oNH-biotinyl 0.65 0.28 30 
z Abu CHr...{:6Hu 0.68 0.044 
z Phe CH2CH(OH)C6F s 0.7 0.35 
z Abu CHr2-furyl 0.8 0.033 
z Abu (CH2hC6Hs 0.8 0.043 
z Abu (CH2JoOH 0.8 0.078 
z Abu CH2CH(OH)C6H4(3-0Ph) 0.9 0.59 35 
z Abu (CH2)o-4-morpholinyl 0.16 
z Abu CH2CH(OH)Ph 1.1 O.G15 
z Abu CHr4-pyridyl 1.1 0.11 
z Abu (CH2h-1-pyrrolidine-2-one 1.2 0.27 
z Phe CH2CH(OH)Ph 1.3 0.05 
z Abu CH2C6H3(3,5-(0CH3)o) 2.3 0.022 40 
z Nva CH2CH(OH)Ph 7.8 11 
z Abu CHr8-caffeinyl 32 4.6 
z Abu n-Pr 0.25 
z Abu CHr3-pyridyl 0.12 
z Phe CH2Ph 0.046 
Axonal degeneration is a feature common to a wide spec-
trum of neurologic disorders and axonal degeneration is the 
pathology that underlies clinical dysfunction in these disor-
ders. These diseases include, peripheral neuropathies due to 50 
genetic mutations, peripheral neuropathies associated with 
other systemic diseases including uremia, rheumatologic dis-
eases, liver diseases, and infections, axonal degeneration sec-
ondary to primary demyelinating disorders including inflam-
matory demyelinating neuropathies and multiple sclerosis. 55 
These a-ketoamide calpain inhibitors will be effective in 
preventing axonal degeneration in these other disorders and 
will thus constitute a novel treatment for these diseases. 
The above specification and Examples fully disclose how 60 
to make and use the methods of the present invention. How-
ever, the present invention is not limited to the particular 
embodiments described herein, but includes all modifications 
thereof within the scope of the following claims. The various 
references to journals, patents, and other publications which 65 
are cited herein comprise the state of the art and are incorpo-
rated herein by reference. 
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What is claimed is: 
1. A method fortreating axonal degeneration of the periph-
eral nervous system of a patient comprising administering to 
the patient a compound selected from the group consisting of: 
Z-Leu-Nva-CO-NH--CH2-2-pyridyl, 
Z-Leu-Abu-CO-NH--CH2CH(OH)C6F 5 , 
Z-Leu-Phe-CO-NH-(CH2)2Ph, 
Z-Leu-Abu-CO-NH--CH2CH(OH)C6H4 -3-0C6H4 (3-
CF3), 
Z-Leu-Abu-CO-NH--CH2CH(OH)C6H4 ( 4-0CH2Ph), 
Z-Leu-Abu-CO-NH--CH2CH(OH)C6H4 (4-0Ph), 
Z-Leu-Phe-CO-NH-CH2-2-quinolinyl, 
Z-Leu-Abu-CO-NH-(CH2)2C6Hi3-0CH3), 
Z-Leu-Abu-CO-NH-(CH2)2C6Hi 4-0CH3), 
Z-Leu-Abu-CO-NH--CH2CH(OH)- l-C10H7 , 
Z-Leu-Phe-CO-NH-(CH2)3-4-morpholinyl, 
Z-Leu-Abu-CO-NH-(CH2)2C6Hi2-0CH3), 
Z-Leu-Abu-CO-NH--CH2-2-quinolinyl, 
Z-Leu-Abu-CO-NH-(CH2)2-2-(N-methylpyrrole), 
Z-Leu-Phe-CO-NH-CH2CH(OH)C6H4 -3-0C6H4 (3-
CF3), 
Z-Leu-Abu-CO-NH-(CH2)2C6H5 , 
Z-Leu-Phe-CO-NH-Et, 
Z-Leu-Abu-CO-NH--CH2CH(OC2H5 ) 2, 
Z-Leu-Phe-CO-NH-CH2CH(OH)C6Hi 4-0Ph), 
Z-Leu-Phe-CO-NH-CH2CH(OH)C6Hi 4-0CH2Ph), 
Z-Leu-Abu-CO-NH--CH2C6H5 , 
Z-Leu-Phe-CO-NH-(CH2)2NH-biotinyl, 
Z-Leu-Phe-CO-NH-( CH2)3 -2-tetrahydroisoquinoli-
ny l, 
Z-Leu-Abu-CO-NH--CH2CH(OH)C6H3(3,4-
(0CH2Ph)2), 
Z-Leu-Abu-CO-NH--CH2CH(OH)C6H4 (4-0CH3), 
Z-Leu-Nva-CO-NH-(CH2)3-4-morpholinyl, 
Z-Leu-Abu-CO-NH--CH2-l -isoquinoliny 1, 
Z-Leu-Abu-CO-NH-Et, 
Z-Leu-Abu-CO-NH--CH2CH(OH)C6H4 -3-0C6H3(3, 
4-Cl2), 
Z-Leu-Abu-CO-NH-Me, 
Z-Leu-Abu-CO-NH-(CH2k 1-imidazolyl, 
Z-Leu-Abu-CO-NH-(CH2)2-3-indolyl, 
Z-Leu-Abu-CO-NH-( CH2)3-2-tetrahydroisoquinoli-
ny l, 
Z-Leu-Abu-CO-NH--CH2-2-tetrahydrofuryl, 
Z-Leu-Abu-CO-NH--CH2CH(OH)C6H4 ( 4-N(CH3)2), 
Z-Leu-Phe-CO-NH-n-Pr, 
Z-Leu-Abu-CO-NH--CH2CH(OH)-2-C10H7 , 
Z-Leu-Phe-CO-NH-Me, 
Z-Leu-Abu-CO-NH--CH2CH(OH)C6H4 (3-CF3), 
Z-Leu-Abu-CO-NH-(CH2k 1-tetrahydroquinolinyl, 
Z-Leu-Abu-CO-NH-(CH2)2C6Hi 4-0H), 
Z-Leu-Abu-CO-NH--CH2CH(OH)C6H2(3,4,5-
(0CH3)3), 
Z-Leu-Phe-CO-NH-( CH2)3-1-tetrahydroquinoliny1, 
Z-Leu-Abu-CO-NH-(CH2)2-2-pyridyl, 
Z-Leu-Abu-CO-NH--CH2-C6Hil,3,3-(CH3)3-5-0H), 
Z-Leu-Phe-CO-NH-CH2CH(OH)C6Hi3-CF 3), 
Z-Leu-Phe-CO-NH-CH2CH(OH)C6H3(3,4-
(0CH2Ph)2), 
Z-Leu-Abu-CO-NH-(CH2)50H, 
Z-Leu-Abu-CO-NH--CH2CH(OCH3)2, 
Z-Leu-Phe-CO-NH-CH2CH(OH)C6H4 -3-0C6H3(3,4-
Cl2), 
Z-Leu-Phe-CO-NH-CH2CH(OH)C6Hi3-0Ph), 
Z-Leu-Phe-CO-NH-CH2CH(OH)C6Hi 4-N(CH3)2), 
Z-Leu-Abu-CO-NH--CH2-2-pyridyl, 
Z-Leu-Abu-CO-NH-(CH2)20(CH2)20H, 
US 7,429,560 B2 
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Z-Leu-Phe-CO-NH-CH2-2-pyridyl, 
Z-Leu-Abu-CO-NH-(CH2)2NH-biotinyl, 
Z-Leu-Abu-CO-NH---CH2---C6H11 , 
Z-Leu-Phe-CO-NH-CH2CH(OH)C6F 5 , 
Z-Leu-Abu-CO-NH---CH2-2-furyl, 
Z-Leu-Abu-CO-NH-(CH2)3C6H5 , 
Z-Leu-Abu-CO-NH-(CH2)20H, 
Z-Leu-Abu-CO-NH---CH2CH(OH)C6H4 (3-0Ph), 
Z-Leu-Abu-CO-NH-(CH2)2-4-morpholinyl, 
Z-Leu-Abu-CO-NH---CH2CH(OH)Ph, 
Z-Leu-Abu-CO-NH---CH2-4-pyridyl, 
Z-Leu-Abu-CO-NH-(CH2k l-pyrrolidine-2-one, 
Z-Leu-Phe-CO-NH-CH2CH(OH)Ph, 
Z-Leu-Abu-CO-NH---CH2C6H3(3,5-(0CH3)2), 
Z-Leu-Nva-CO-NH---CH2CH(OH)Ph, 
Z-Leu-Abu-CO-NH---CH2-8-caffeiny 1, 
Z-Leu-Abu-CO-NH-n-Pr, 
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Z-Leu-Abu-CO-NH---CH2-3-pyridyl, 
Z-Leu-Phe-CO-NH-CH2Ph, and 
Z-Leu-Abu-CONH-(CH2)3-4-morpholinyl; 
wherein Z is a benzyloxycarbonyl group. 
2. The method of claim 1, wherein the compound is Z-Leu-
Abu-CONH-(CH2)3-4-morpholinyl. 
3. The method of claim 1, wherein the axonal degeneration 
of the peripheral nervous system is chemically-induced 
axonal degeneration. 
10 4. The method of claim 1, wherein the compound is admin-
istered concurrently with an anti-hyperproliferative agent. 
5. The method of claim 1, wherein the compound is admin-
istered subsequent to administration of an anti-hyperprolif-
erative agent. 
15 6. The method of claim 1, wherein the compound is admin-
istered orally. 
* * * * * 
